Literature DB >> 19508

Clinical pharmacokinetics of lorazepam. III. Intravenous injection. Preliminary results.

D J Greenblatt, W H Comer, H W Elliott, R I Shader, J A Knowles, H W Ruelius.   

Abstract

Four healthy male volunteers received 5 mg lorazepam as a single intravenous injection. Concentrations of lorazepam and its glucuronide metabolite were determined in multiple venous blood samples drawn during the 48 hours after dosing and in all urine collected during 96 hours after the dose. Mean pharmacokinetic parameters for lorazepam were: apparent elimination half-life, 13.2 hours; volume of distribution, 0.84 liter/kg; total clearance, 55.3 ml/min. Lorazepam glucuronide, the major metabolic product of lorazepam, promptly appeared in blood, reached peak levels within 6 hours of the dose, then declined in parallel with the parent compound. A mean of 69 per cent of the dose was recovered in urine as lorazepam glucuronide.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 19508     DOI: 10.1002/j.1552-4604.1977.tb05641.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  9 in total

Review 1.  Relationships between CSF drug concentrations, receptor binding characteristics, and pharmacokinetic and pharmacodynamic properties of selected 1,4-substituted benzodiazepines.

Authors:  W A Colburn; M L Jack
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

2.  Neurology-important advances in clinical medicine: Lorazepam: a new antiepileptic drug in status epilepticus therapy.

Authors:  N S Chu
Journal:  West J Med       Date:  1982-10

3.  Pharmacokinetics of intravenous lorazepam in pediatric patients with and without status epilepticus.

Authors:  James M Chamberlain; Edmund V Capparelli; Kathleen M Brown; Cheryl W Vance; Kathleen Lillis; Prashant Mahajan; Richard Lichenstein; Rachel M Stanley; Colleen O Davis; Stephen Gordon; Jill M Baren; John N van den Anker
Journal:  J Pediatr       Date:  2011-11-01       Impact factor: 4.406

4.  Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation.

Authors:  D J Greenblatt; M D Allen; D S MacLaughlin; D H Huffman; J S Harmatz; R I Shader
Journal:  J Pharmacokinet Biopharm       Date:  1979-04

Review 5.  Clinical pharmacokinetics of oxazepam and lorazepam.

Authors:  D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1981 Mar-Apr       Impact factor: 6.447

6.  A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam.

Authors:  A R Maharaj; J S Barrett; A N Edginton
Journal:  AAPS J       Date:  2013-01-24       Impact factor: 4.009

7.  The pharmacokinetics and biotransformation of the new benzodiazepine lormetazepam in humans. I. Absorption, distribution, elimination and metabolism of lormetazepam-5-14C.

Authors:  M Hümpel; V Illi; W Milius; H Wendt; M Kurowski
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1979       Impact factor: 2.441

8.  Pharmacokinetics and clinical efficacy of lorazepam in children with severe malaria and convulsions.

Authors:  Simon N Muchohi; Kenneth Obiero; Charles R J C Newton; Bernhards R Ogutu; Geoffrey Edwards; Gilbert O Kokwaro
Journal:  Br J Clin Pharmacol       Date:  2007-07-17       Impact factor: 4.335

9.  Dose-dependent effects of intravenous lorazepam on cardiovascular activity, plasma catecholamines and psychological function during rest and mental stress.

Authors:  J H Tulen; P Moleman; F Boomsma; H G van Steenis; V J van den Heuij
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.